Incyte

United Therapeutics

Gilead Sciences

Natera

Neurocrine Biosciences

Alnylam Pharmaceuticals

Vertex Pharmaceuticals

Insmed

Sarepta Therapeutics

Viking Therapeutics

SPDR S&P Biotech ETF

XBI tracks an equal-weighted index of US biotechnology stocks.

Direxion Daily S&P Biotech Bull 3X Shares

Invesco Dynamic Biotechnology & Genome ETF

Discover why biotech stocks are surging despite large fund outflows. Monitor these three industry ETFs for "buy the dip" opportunities.

Where to Buy Booming Biotech ETFs

ARK Genomic Revolution Multi-Sector ETF

VanEck Vectors Biotech ETF

Virtus LifeSci Biotech Products ETF

Principal Healthcare Innovators Index ETF

Loncar Cancer Immunotherapy ETF

First Trust NYSE Arca Biotechnology Index Fund

iShares Nasdaq Biotechnology ETF

ALPS Medical Breakthroughs ETF

Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to work in favor of the biotech market.

A Guide to Biotech ETF Investing

CRISPR Therapeutics

Global Blood Therapeutics

Novartis

Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to drive the biotech market.

Why Biotech ETFs Surged in Monday's Trading Session

iShares North American Tech-Software ETF

Technology Select Sector SPDR Fund

Health Care Select Sector SPDR Fund

While the market will eventually need to vent and pull back, buyers remain in control, with buying in software and biotech.

Big Buying in Software and Biotech Stocks Is Bullish

Invesco DWA Healthcare Momentum ETF

Decent fundamentals and valuations as well as encouraging developments put these medical ETFs and stocks in focus.

Healthcare Drives Wall Street: 5 Soaring ETFs

iShares U.S. Medical Devices ETF

iShares S&P 500 Value ETF

Health-care stocks are poised to win out no matter which way the value-versus-growth debate swings, says Christian Fromhertz, founder and CEO of Tribeca Trade Group.

As the value-growth battle rages, this sector is winning on both sides, says trader

iShares MSCI Emerging Markets ETF

iShares U.S. Regional Banks ETF

iShares Transportation Average ETF

KB Financial Group

Invesco KBW Bank ETF

SPDR S&P Regional Banking ETF

VanEck Vectors Oil Services ETF

Invesco WilderHill Clean Energy ETF

First Trust NASDAQ Clean Edge Green Energy Index Fund

Vanguard Health Care ETF

Energy Select Sector SPDR Fund

SPDR S&P Oil & Gas Exploration & Production ETF

SPDR S&P Transportation ETF

Morgan Stanley outlined four outcomes of the 2020 election and its strategies for investors on how to make the most of them.

Follow Morgan Stanley to Trade 2020 Election With ETFs

Biotechnology stocks have been outperforming over the past month, but ETF investors seem disinterested and are even trimming exposure to this sector.

The Unloved Biotechnology ETF Rally

Virtus LifeSci Biotech Clinical Trials ETF

Global X Genomics & Biotechnology ETF

iShares U.S. Healthcare Providers ETF

SPDR S&P Pharmaceuticals ETF

The healthcare sector, which has been the second-worst performer among the 11 major S&P 500 sectors this year, took the center stage this month with some outperformance compared to other sectors.

Healthcare ETFs Win in October: Here's Why

These exchange-traded funds offer investors an easy way to potentially profit from growth in the healthcare sector.

5 Top Healthcare ETFs

The SPDR S&P Biotech ETF (XBI) and rival biotechnology ETFs are coming off the third quarter and have recently been beset by outflows, but some market observers believe the group offers rebound potential.

Readying For a Biotech Bounce With XBI

Investors continued to yank money out of biotechnology sector-related ETFs for the seventh consecutive week, the longest back-to-back weekly selling since late 2017. According to PiperJaffray analyst Christopher Raymond’s weekly note, investors withdrew money out of healthcare/biotech-specific funds, Barron’s reports.

Biotech ETFs Suffer Seventh Week of Outflows

Many biotech ETFs and other funds have fallen sharply off their highs in recent months.

Investors flee Biotech ETFs as they Lag Bull Market

Amid intensifying scrutiny of drug pricing and other political pressures, biotechnology ETFs and active mutual funds endured some rough sledding in the third quarter. The iShares Nasdaq Biotechnology ETF (IBB), VanEck Vectors Biotech ETF (BBH) and the equal-weight SPDR S&P Biotech ETF (XBI) are all saddled with third-quarter losses and data suggest investors have been fleeing [.

Biotech ETFs Had A Rough Third Quarter

Alerian MLP ETF

iShares Core Dividend Growth ETF

WisdomTree India Earnings Fund

iShares Russell 1000 Value ETF

iShares Russell 1000 Growth ETF

Invesco Emerging Markets Sovereign Debt ETF

Invesco S&P 500 Low Volatility ETF

SPDR Portfolio S&P 500 Growth ETF

iShares Edge MSCI Min Vol USA ETF

Today’s market landscape is presenting investors with a challenging environment where value is starting to supplant growth in what has been a historical bull run the past decade. Investors who haven’t yet considered the benefits of smart beta exchange-traded funds (ETFs) may want to see which ones have been the most active thus far to [.

10 Most Active Smart Beta ETFs

Invesco S&P SmallCap Health Care ETF

The healthcare sector has been the worst performing on the S&P 500 in 2019, but these biotech ETFs are still worth a look.

Biotech ETFs That Should Remain Healthy

SPDR Bloomberg Convertible Securities ETF

SPDR S&P International Dividend ETF

SPDR Gold MiniShares Trust

SPDR S&P Bank ETF

SPDR S&P Dividend ETF

SPDR Portfolio Emerging Markets ETF

SPDR ETFs span an array of asset classes, including stocks, bond, commodities and real estate, among others. Here are 7 of the best ETFs to buy from SPDR.

7 of the Best SPDR ETFs — Besides SPY and GLD

Alexion Pharma

Amgen

Editas Medicine

Seven simple steps to improving your chances of success in this part of the market.

How to Invest in Biotech Stocks

Despite health care's 2019 woes, one top technician says there are clear signs that a big breakout in one piece of the health-care trade is finally coming to life.

Top market technician says the biotech breakout is just getting started

Pfizer struck a deal to acquire the cancer drugmaker Array Biopharma for $11 billion in an all-cash consideration.

Pfizer-Array Biopharma Deal Bump Up Biotech ETFs

Pfizer's deal to buy Array BioPharma for $10.6 billion has ignited biotech stocks. There are ways to get in on the rally using exchange-traded funds.

Biotech ETFs are breaking out—here are 3 ways to play the space

Institutional players are abandoning biotech funds at a rapid pace, raising the odds that the sector will enter a bear market.

Biotech Sector Could Enter Bear Market

Illumina

Intuitive Surgical

Johnson & Johnson

Teladoc

The global demand for healthcare products and services will keep growing significantly. Here's your complete guide to finding the best healthcare stocks and ETFs.

Everything You Need to Know About Investing in Healthcare

Biogen

Bristol-Myers

Celgene

Regeneron Pharmaceuticals

When the stock market is hitting record highs, it’s important to remember that it’s really a market of stocks rather than a stock market. Not all companies are created equal. Nor are all sectors.

Top Biotech Stocks and ETFs: A Sector in Trouble or a Huge Bargain

First Trust Materials AlphaDEX Fund

Invesco DWA Technology Momentum ETF

PowerShares Russell Midcap Pure Growth Portfolio

Vanguard Russell 2000 Growth 

High-beta ETFs & stocks seek to capitalize on continued growth with market-beating returns.

News for SPDR S&P Biotech ETF ETF (XBI)